GlassScriptPhysician profile
Amy L Agena
NPI 1114195526
$3,426.58
in general payments reported to CMS, 2019-2025
33 companies · $922 in 2025
The $922 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $617 · 2022: $701 · 2023: $695 · 2024: $491 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,108.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,528.91 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $549.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $147.35 | 2021-2025 | Jardiance, Mounjaro |
| Astellas Pharma US INC | $120.06 | 2023-2024 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $117.37 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $112.44 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.91 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.23 | 2021-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $66.90 | 2022 | |
| Abbott Laboratories | $48.17 | 2024-2025 | Freestyle Libre 3 |
| Boston Scientific Corporation | $47.85 | 2025 | General - Pain Management |
| Axsome Therapeutics, INC. | $40.53 | 2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $39.58 | 2025 | Spravato |
| Sanofi Pasteur INC. | $38.15 | 2023-2024 | |
| Esperion Therapeutics, INC. | $37.58 | 2023-2025 | Nexletol |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $32.02 | 2023-2024 | Uptravi, Opsumit |
| Idorsia Pharmaceuticals US INC | $30.51 | 2022-2023 | Quviviq |
| Azurity Pharmaceuticals, INC. | $29.96 | 2023 | Horizant |
| Kowa Pharmaceuticals America, INC. | $27.72 | 2022 | |
| Merck Sharp & Dohme LLC | $27.58 | 2021-2025 | Vaxelis, Proquad, Gardasil 9 |
| Supernus Pharmaceuticals, INC. | $25.80 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $23.16 | 2023 | Rexulti |
| Biogen, INC. | $22.49 | 2025 | Zurzuvae |
| Optinose US, INC. | $19.96 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.76 | 2021 | |
| Dexcom, INC. | $17.18 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.52 | 2024 | Xifaxan |
| Neos Therapeutics, LP | $15.08 | 2024 | Adzenys Xr-Odt |
| Glaxosmithkline, LLC. | $14.75 | 2021 | |
| Eisai INC. | $14.09 | 2021 | |
| Medtronic, INC. | $13.55 | 2023 | Kyphon Express II Kyphopak Tray |
| Exact Sciences Corporation | $13.13 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Agena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.